Chemiluminescence Immunoassay Market Size, Share and Trends 2026 to 2035

Revenue, 2025

USD 8.37 Bn

Forecast Year, 2035

USD 17.24 Bn

CAGR, 2026 - 2035

7.49%

Report Coverage

Global

What is the Chemiluminescence Immunoassay Market Size?

The global chemiluminescence immunoassay market size is calculated at USD 8.37 billion in 2025 and is predicted to increase from USD 9.01 billion in 2026 to approximately USD 17.24 billion by 2035, expanding at a CAGR of 7.49% from 2026 to 2035. The chemiluminescence immunoassay market is experiencing significant growth due to the increasing emphasis on early disease detection. Furthermore, rising investments in drug discovery and development contributes to market expansion.

Chemiluminescence Immunoassay Market Key Takeaways

• North America held market share of 52% in 2025.
• By application, the endocrine segment is expected to captured the biggest revenue share in 2025.
• By product, the consumables segment is expected to acquire the largest share in 2025.
• By end-users, the hospitals segment registered a maximum market share in 2025.

What is a Chemiluminescence Immunoassay?

Chemiluminescence immunoassay is a detection technique that uses a chemiluminescent label to tag antibodies or antigens, enabling highly sensitive and automated diagnostic testing in clinical settings. Chemiluminescence immunoassay is a cutting-edge diagnostic technology, combining sensitivity, automation, and versatility. Its wide applications in clinical diagnostics, environmental monitoring, and pharmaceuticals drive its demand. From detecting COVID-19 antibodies to measuring cancer biomarkers, CLIA is reshaping clinical diagnostics and increasing the market.

Impact of AI on the Chemiluminescence Immunoassay Market

The integration of AI algorithms in chemiluminescence immunoassay improves the accuracy and efficiency of diagnostic processes. AI-powered advancements enhance data interpretation and decrease human errors. AI can quickly analyze vast amounts of data, providing faster and more accurate results. This allows healthcare professionals to make timely decisions. Moreover, integrating AI technologies in the manufacturing processes of CLIA automates and optimizes workflows, decreases overall operational costs, and enables high-throughput testing.

Chemiluminescence Immunoassay Market Outlook

• Industry Growth Overview: Immunoassays remain the most popular among customers due to their versatility and quick turnaround time. Growth avenues include expanding applications in personalized medicine, environmental monitoring, and point-of-care testing.
• Global Expansion: The global expansion is driven by increasing demand for accurate, high-throughput diagnostic testing across hospitals, diagnostic laboratories, and research institutions. Emerging markets are also contributing significantly to market growth through expanding healthcare infrastructure and improved access to advanced diagnostic technologies.
• Sustainability Trends: As a greener alternative, chemiluminescence lowers environmental impact by eliminating radioactive waste disposal concerns, aligning with global sustainability initiatives. Additionally, emphasis on sustainability by using eco-friendly materials in manufacturing can appeal to environmentally conscious consumers.
• Major investors: F.Hoffmann-La Roche Ltd and Abbott Laboratories are investing in innovative products and strong R&D investments, improving their market presence. BioMerieux SA and Maccura Biotechnology Co., Ltd. offer unique testing solutions that meet the need of specific diagnostic needs, contributing to niche markets.

Market Trends

• The trend towards personalized medicine is growing the demand for chemiluminescence immunoassay tests that offer specific and individualized diagnostic data.
• Technologies such as CLEIA, Enzyme-Linked Immunosorbent Assay, and Radioimmunoassay are widely used. However, CLEIA has emerged as a game-changer due to its improved sensitivity and specificity.
• There is a growing trend of automation. Fully automated platforms are streamlining laboratory workflows, decreasing manual errors, and rising throughput in hospital and reference labs.
• The growing adoption of POCT devices for immunoassay-based diagnostics is enhancing accessibility to healthcare in rural and semi-urban areas.

Chemiluminescence Immunoassay Market Growth Factors

• Increasing demand for accurate diagnostic tests is a major factor boosting the growth of the market.
• The rising burden of chronic diseases fuels the market growth.
• Rising research and development activities in the fields of pharmaceutical and biotechnology contribute to market expansion.
• Ongoing technological advancements led to innovations in CLIA, such as automated systems and high-throughput screening, which influence the market.
• Increasing government funding for novel drug development contributes to market growth.

Market Scope

Market Dynamics

Driver

With the rising number of cases of chronic diseases, such as cancer and diabetes, the demand for CLIA is increasing. CLIA, a powerful diagnostic technique, plays a crucial role in detecting disease patterns in patients with cancer and diabetes. The growing global population, coupled with an increase in chronic diseases, is significantly driving up the demand for these essential diagnostic tools. In response to this heightened demand, ongoing research and development in CLIA technology is fostering the innovation of new products with enhanced performance and efficiency. Innovations in this field may include improved sensitivity, which requires convenient testing to achieve accurate diagnostic tests.

Restraint

Despite their widespread use, price fluctuations influenced by geopolitical events and global economic conditions can lead to significant variations in production costs, consequently impacting the overall profitability of companies operating within the CLIA market. Furthermore, the chemiluminescence immunoassay industry is characterized by strict regulatory requirements, which can potentially increase the costs of product development, and this will cause hindrance in the market, consequently affecting the profitability of numerous players ranging from large multinational corporations to smaller regional companies vying for market share.

Opportunity

There are substantial opportunities for the growth of CLIA in the healthcare sector. The integration of CLIA with conventional drug development, particularly in areas such as chronic disease and veterinary diagnostics, presents a promising avenue for development. This holistic approach can enhance patient comfort, reduce reliance on pharmaceuticals, and improve quality of life. Continued research and development aimed at scientifically validating the efficacy and safety of CLIA also play a crucial role in addressing existing concerns. By establishing robust clinical evidence and integrating CLIA into mainstream drug development and research practices, the credibility of this natural treatment can be significantly enhanced, fostering greater acceptance and use to research and monitor therapeutic response.

Segment Insights

Application Insights

Which Application Segment Dominated the Chemiluminescence Immunoassay Market in 2025?

The endocrinology segment dominated the market in2025, driven by increased routine testing like Thyroid Stimulating Hormone. Introduction of new tests for diagnosing several endocrine disorders increases the demand for the endocrine segment in the market. For instance, TSH HumaCLIA SR is a chemiluminescent immunoassay for the quantitative determination of thyroid stimulating hormone in human serum and plasma.

The oncology segment is anticipated to grow at the fastest rate during the predicted timeframe, driven by rising prevalence of cancer, which requires early diagnosis. Chemiluminescence can diagnose various types of cancer markers in body fluids and tissues at a very early stage, thus offering patients the opportunity for early detection and treatment. Another contribution of chemiluminescence in tumor therapy is the possibility of using chemiluminescence to detect reactive oxygen species, thereby allowing dose detection for photodynamic tumor therapy.

Product Insights

Why Did Consumables Segment Hold the Largest Share of the Market in 2025?

The consumables segment held the largest share of the market in 2025, due to rising need for supplies like reagents and stains in therapeutic drug monitoring, endocrinology, and disease diagnosis. Furthermore, demand for assay kits and reagent packs in hospitals and reference laboratories has increased because test volumes for cancer biomarkers, infectious diseases, endocrine disorders, cardiac markers, and therapeutic drug monitoring have increased.

The instrument segment is expected to grow at the fastest rate during the forecast period, as they are mainly used in high-volume testing settings, such as large hospitals and research institutes, where efficiency and accuracy are important. Manufacturers are investing in automation, miniaturization, and faster throughput, making CLIA systems more accessible to both large hospitals and smaller diagnostic centers.

End-user Insights

Which End Use Segment Dominated the Chemiluminescence Immunoassay Market in 2025?

The hospital segment dominated the market in 2025, due to increasing need for chemiluminescence immunoassay solutions in hospitals and growing hospital visits for infectious diseases and cancer. Correspondingly, the growing hospitalization owing to the outbreak of novel coronavirus is expected to increase the requirement for chemiluminescence immunoassay solutions in the hospital segment. Rising applications of automated CLIA analyzers in oncology, therapeutic drug monitoring, and companion diagnostics and the emergence of integrated modules of automated CLIA analyzers are projected to fuel the growth of the hospital segment.

The clinical laboratories segment is expected to grow at the fastest rate during the forecast period, due to its growing volume of testing and outsourcing for hospitals. Some of the commonly used techniques used in clinical laboratories to diagnose infectious diseases involve microscopy, culture, immunological tests, and nucleic acid-based identification methods.

Regional insights

What is the U.S. Chemiluminescence Immunoassay Market Size?

The U.S. chemiluminescence immunoassay market size is exhibited at USD 3.03 billion in 2025 and is projected to be worth around USD 6.52 billion by 2035, growing at a CAGR of 7.96% from 2026 to 2035.

North America seized the substantial market stake globally in 2025 and is projected to mirror this trend during the assessment period. Significant influences backing to its governance are the existence of established healthcare infrastructure, high acceptance of cutting-edge chemiluminescence immunoassay solutions, and snowballing pervasiveness of chronic diseases among others. Additionally, augmented availability of novel CLIA systems in the U.S. on account of existence of crucial market participants like Beckman Coulter, Inc., Abbott Laboratories, Roche and DiaSorinis further likely to subsidize the growth of the market in the North America.

U.S. Chemiluminescence Immunoassay Market Trends

The U.S. market is experiencing strong growth, driven by increasing rate of chronic diseases, aging populations, and requirement for advanced, automated diagnostics with high sensitivity.

Asia Pacific Poised for Rapid Growth in the Chemiluminescence Immunoassay Analyzers Market

Asia Pacific is prospective to be an extremely profitable market for the chemiluminescence immunoassay analyzers market and it is anticipated to develop at a rapid growth rate throughout the estimate period. Huge population base and escalation in occurrence of infectious and chronic diseases augments requirement for diagnostic testing in the APAC. Besides, promising government initiative to progress healthcare infrastructure is expected to supplement the growth of the market.

China Chemiluminescence Immunoassay Market Analysis

China's market is experiencing robust expansion, driven by increasing chronic diseases, technological advancements, and even a shift towards advanced diagnostics, with remarkable dominance by foreign players such as Roche, though strong local firms (Snibe, Mindray, Autobio) are rapidly gaining share with affordable options, quality, focusing on high sensitivity/automation for oncology, infectious diseases, and endocrinology.

European Rapid Growth in the Chemiluminescence Immunoassay Industry

The chemiluminescence immunoassay industry in Europe is growing steadily due to the high prevalence of chronic diseases and strong demand for advanced diagnostic solutions. Increasing adoption of automated and high-throughput immunoassay systems is enhancing laboratory efficiency and accuracy. Additionally, well-established healthcare infrastructure and ongoing technological innovations are supporting sustained market expansion.

UK Chemiluminescence Immunoassay Market Trends

The UK chemiluminescence immunoassay market is undergoing strong growth, driven by rising chronic diseases, need for high sensitivity, and tech advances such as automation/AI, with reagents leading sales but fast growth in point-of-care along with digital integration.

Latin American Advancements in the Chemiluminescence Immunoassay Industry

Latin America is expected to witness a substantial amount of growth in the market. This growth is driven by increasing healthcare investments, rising awareness of early disease detection, and a growing population. Countries like Brazil and Mexico are leading players in the region as they are supported by robust government initiatives aimed at enhancing healthcare infrastructure and access to advanced diagnostic technologies.

Brazil Chemiluminescence Immunoassay Market Trends

The country's market landscape is evolving, with a high focus on affordability and accessibility of diagnostic solutions. The increasing prevalence of chronic diseases and the demand for point-of-care testing are further propelling the market. Additionally, expanding healthcare infrastructure, entry of global diagnostic companies, and ongoing regulatory approvals are supporting market growth.

MEA's Growing Chemiluminescence Immunoassay Industry

The Middle East and Africa region is set to experience a steady growth rate throughout the forecast years, driven by increasing healthcare investments, rising awareness of diagnostic testing, and government initiatives aimed at improving healthcare infrastructure. Countries like South Africa and the UAE are leading players as they have a strong focus on enhancing laboratory capabilities and access to advanced diagnostic technologies. The region is characterized by a mix of local and international players, all competing for market share.

Saudi Arabia Chemiluminescence Immunoassay Market Trends

The country's potential for growth is quite substantial, and this growth is driven by the increasing prevalence of infectious diseases and a growing emphasis on preventive healthcare. As healthcare systems evolve, the demand for CLIA analyzers is expected to rise even more. Adoption of automated and high-throughput diagnostic systems is expanding across hospitals and clinical laboratories. Additionally, government healthcare investments and ongoing modernization initiatives are supporting market growth.

Value Chain Analysis of Chemiluminescence Immunoassay Market

• Distribution to Hospitals, Pharmacies
  It is primarily achieved by offering high-volume testing environments, guaranteeing widespread patient access, and even integrating with established healthcare infrastructure.
• Patient Support and Services
  It focusses on improving the overall diagnostic experience and enhancing patient management and results. These services are generally offered indirectly via healthcare providers, with a rising integration of digital technologies and also at-home solutions.

Competitive landscape

The competitive landscape of the chemiluminescence immunoassay market is characterized by a combination of innovation, strategic collaborations, and ongoing research advancements. As companies continue to invest in technology and streamline operations, the market is experiencing a significant shift towards more efficient and accurate diagnostic solutions. The market is highly competitive, with key players such as Abbott Laboratories, DiaSorin S.p.A., Immunodiagnostic Systems, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., and Siemens Healthineers.

Chemiluminescence Immunoassay Market Comapnies

• DiaSorin S.p.A.: DiaSorin S.p.A. is a prominent manufacturer in the chemiluminescence immunoassay (CLIA) market, providing a comprehensive portfolio of many fully automated analyzers and also a broad, specialized menu of diagnostic tests (reagents) for a broad range of clinical areas.
• Ortho Clinical Diagnostics: Ortho Clinical Diagnostics provides integrated, automated VITROS Systems for chemistry and immunoassays, aiming on high efficiency, accuracy (high first-pass yield), and also workflow optimization with a wide menu of CLIA assays for infections, cardiac markers, cancer, and more, all on a single platform, well-known for its waterless operation along with reliability in clinical labs.
  (Source: precedenceresearch.com/)

Other major Key Players

• Hoffmann-La Roche AG
• Siemens Healthineers
• Abbott Laboratories
• Immunodiagnostic Systems
• Beckman Coulter Inc.
• Inova Diagnostics, Inc.
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
• Maccura Biotechnology Co., Ltd
• Others

Recent Collaboration

• In July 2026 announcement from AnteoTech, which confirmed the completion of the first stage of a collaborative development program assessing the effectiveness of AnteoBind NXT in activating magnetic particles for application in the global chemiluminescent immunoassay (CLIA) market. This initial program, which commenced in March 2026, has evaluated the performance and cost-effectiveness of AnteoBind NXT activated magnetic particles for large-scale automated CLIA diagnostic testing and has been completed in accordance with the scheduled timeline.
• In January 2024, Fujirebio Holdings and Agappe Diagnostics announced their partnership through a Contract Development and Manufacturing Organization (CDMO) agreement for the manufacturing of cartridge-based CLIA system reagents for the immunology equipment Mispa i60 and Mispa i121. Importantly, the analyzers and reagents will be marketed under Agappe's brand, establishing Agappe as the first Indian company to provide a comprehensive Chemiluminescence Solution that includes locally manufactured reagents.
  (Source: https://www.theaustralian.com.au)
  (Source: https://biopharmaapac.com)

Segments Covered in the Report

By Product

• Consumables
• Instruments
• Automated
• Semi-automated
• Software & Services

By Application

• Cardiology
• Therapeutic Drug Monitoring
• Oncology
• Endocrinology
• Autoimmune Disease
• Infectious Disease
• Others

By End-use

• Clinical Laboratories
• Hospitals
• Pharmaceutical & Biotechnology Companies
• Others

By Regional Outlook

• North America
  • U.S.
  • Canada
• Europe
  • U.K.
  • Germany
  • Italy
  • France
  • Rest of EU
• Asia Pacific
  • China
  • India
  • Japan
  • Southeast Asia
  • Rest of APAC
• Middle East & Africa
  • GCC
  • North Africa
  • South Africa
  • Rest of Middle East and Africa
• Latin America
  • Argentina
  • Mexico
  • Brazil
  • Rest of Latin America